Why the study?
Does combination antihypertensive therapy improve blood pressure control and surrogate cardiovascular markers compared to monotherapy in hypertensive patients?
Does combination antihypertensive therapy improve blood pressure control and surrogate cardiovascular markers compared to monotherapy in hypertensive patients?
Combination antihypertensive therapy, particularly fixed low-dose combinations, is highly effective and well-tolerated for achieving blood pressure targets and improving target organ damage compared to monotherapy.
Answers are grounded in this paper and cite their sources.
Should not yet change first-line hypertension practice; leaves open the role of fixed-dose combinations pending randomized confirmation.
Pharmacological treatment of hypertension represents a cost-effective way for preventing cardiovascular and renal complications. To benefit maximally from antihypertensive treatment blood pressure (BP) should be brought to below 140/90 mmHg in every hypertensive patient, and even lower (< 130/80 mmHg) if diabetes or renal disease co-exists. Most of the time such targets cannot be reached using monotherapies. This is especially true in patients who exhibit a high cardiovascular risk. The co-administration of two agents acting by different mechanisms considerably increases BP control. Such preparations are not only efficacious, but also well tolerated, and some fixed low-dose combinations have a tolerability profile similar to placebo. This is for instance the case for the preparation containing the angiotensin-converting enzyme inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), a fixed low-dose combination that has recently been shown in controlled interventional trials to be more effective than monotherapies in reducing albuminuria, regressing cardiac hypertrophy and improving macrovascular stiffness. Fixed-dose combinations are becoming more and more popular and are even proposed by current hypertension guidelines as a first-line option to treat hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Struijker-Boudier et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: